Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Original Date: 
August 2005
Revised Date: 
December 2019
  • Diuresis for reduction of edema secondary to cardiac, hepatic or renal dysfunction
  • Useful in the treatment of acute congestive heart failure and pulmonary edema
Reconstitution and Stability: 
  • Stable at room temperature. Protect from light
  • Available as 10 mg/mL solution 
  • Exposure to light may cause discolouration. DO NOT use if solution is yellow          
  • Furosemide is unstable in acidic media but very stable in basic media
  • Solutions stable 24 hours at room temperature in a syringe

- Solutions Compatible: dextrose up to D20W, NS, dextrose-saline combinations, ringer's lactate

- Additives/Above Cassette Compatible: KCl (up to 40 mmol/L)

- Y-site Compatible: heparin, epinephrine, fentanyl, hydromorphone, meropenem, morphine, nitroglycerin, norepinephrine, TPN (amino acid/dextrose)

- Incompatible: azithromycin, ciprofloxacin, diazepam, dobutamine, dopamine, erythromycin, filgrastim, fluconazole, gentamycin, meperidine, midazolam, ondansetron, thiopental



(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct

Yes  -Max 1 mg/kg/dose.  Dose >1mg/kg/dose must be given IV intermittent

Usual dilution: 1 mg/mL

Infusion time: 5 minutes

Infusion rate: do not exceed 0.5 mg/kg/min for doses < 120 mg; 4 mg/min for doses > 120 mg

IV Intermittent Infusion


Usual dilution: 1 mg/mL

Infusion time: 10-15  minutes

Infusion rate: do not exceed 0.5 mg/kg/min for doses < 120 mg; 4 mg/min for doses > 120 mg

IV Continuous Infusion YES
Usual dilution: 1 mg/mL or 10mg/mL

Click here to access SDC Drug Infusion Sheet


(For neonatal dosages, refer to Neonatal IV Drug Manual.)


  • 0.5-2 mg/kg/dose IM/IV Q 4-24 hours.
  • Dose may be increased to achieve desired response
  • Maximum: 6 mg/kg/dose. Most cases not necessary to exceed 4 mg/kg/dose
  • Continuous Infusion: 0.05-0.4 mg/kg/hour, titrate to clinical effect


  • 20-40 mg/dose IM/IV, repeat in 1-2 hours prn, usual Q 6-12 hours
  • Increase dose by 20 mg till desired affect achieved
  • Maximum: 80 mg as a single IV dose
  • Continuous Infusion: 0.1 - 0.4 mg/kg/hour
Potential hazards of parenteral administration: 
  • IM - transient pain at injection site                                             
  • Hypovolemia, hypotension
  • Ototoxicity (deafness, tinnitus) may be associated with large IV doses and rapid injection especially in patients with pre-existing renal impairment or taking other ototoxic drugs
  • Hypokalemia, hypochloremia, hypomagnesemia, hypocalcemia, hyponatremia, hypovolemia, alkalosis, dehydration, hyperuricemia
  • Dermatitis, pruritis, blurred vision, dizziness, bladder spasms, pancreatitis, hyperglycemia in diabetics, thrombocytopenia, agranulocytosis


  • Monitor electrolytes frequently, renal function and blood pressure
  • Caution in patients with complete renal shutdown, hepatic coma, or electrolyte depletion
  • Potentiates antihypertensives
  • May precipitate gout, hyperglycemia in diabetics
  • Cross sensitivity with sulfonamides possible

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.